46% of women still had migraines after menopause

MIGRAINE PATTERN SHIFTS

6 min read

The migraines used to arrive on a schedule you could almost predict. Now they come without warning, at a different intensity, and last week there was a visual disturbance that was never part of them before. Migraine affects women three times more often than men. That ratio exists because of estrogen. And perimenopause is when the estrogen environment becomes most unstable.

The change in pattern is real. The migraine brain is responding to a hormonal signal that lost its rhythm, and you were never told to expect it.

Estrogen withdrawal is a recognized trigger for migraine without aura. Menstrual migraine attacks are tightly linked to the estrogen drop before bleeding. During perimenopause, that withdrawal becomes unpredictable, and so does the migraine pattern. Frequency can increase. Attacks that were previously manageable can become harder to abort.

Some women experience their first-ever migraine aura during perimenopause. A 2026 narrative review in Headache noted that aura can develop as a new phenotypic feature, including visual and sensory symptoms, sometimes occurring without headache. This matters: migraine with aura carries an independent association with ischemic stroke.

What happens after menopause depends on the type. Migraine without aura often improves once estrogen stabilizes at a lower level. Migraine with aura tends to persist. And the common reassurance that menopause will end the migraines is contradicted by population data showing that a substantial proportion of women continue having attacks well into their sixties.

WHAT IT DOES NOT ESTABLISH

No study has established whether the pattern change in any individual is driven primarily by estrogen instability, sleep disruption, vasomotor symptoms, or the mood changes that accompany the transition. All co-occur and all affect migraine threshold. The estrogen hypothesis is well supported but does not account for every attack.

ESTROGEN, SEROTONIN, AND CGRP

Estrogen modulates serotonin and calcitonin gene-related peptide (CGRP), both central to migraine pathophysiology. When estrogen drops, serotonin levels in the trigeminal ganglia change and CGRP release increases. During perimenopause, these drops become unpredictable, repeatedly crossing the threshold that triggers an attack. CGRP is now the target of the most effective class of migraine-specific care available.

THE NUMBERS

3:1

Female-to-male migraine ratio. The disparity is driven by estrogen fluctuations across the reproductive years and peaks during perimenopause.

46%

Of women still had migraine attacks after menopause. One in five continued past age 60. Population study of nearly 5,000 women, 2025.

The second figure matters because of what women are often told: that menopause will fix their migraines. For nearly half the population in this study, the attacks continued. The pattern shifted, and for some the attacks changed character entirely. That is its own kind of disorientation.

A woman sitting at the edge of a bed in a dim room with curtains drawn

THE INTERVENTION WITH THE STRONGEST EVIDENCE

CGRP-targeting preventive therapy

AHS FIRST-LINE POSITION, 2024

The American Headache Society updated its position in 2024: therapies targeting calcitonin gene-related peptide (CGRP) are a first-line option for reducing migraine frequency. This includes monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and small-molecule receptor antagonists (rimegepant, atogepant).

These approaches are migraine-specific. They target the CGRP mechanism directly. The American Headache Society position states they should not require prior failure of older classes before being prescribed.

“The CGRP-targeting therapies should be considered as a first-line approach for migraine prevention along with previous first-line treatments without a requirement for prior failure of other classes of migraine preventive treatment.”

AMERICAN HEADACHE SOCIETY POSITION STATEMENT, HEADACHE, 2024

WHAT IT IS NOT

CGRP therapies require a prescription and evaluation by a headache specialist or neurologist. They are significantly more expensive than older options, though the American Headache Society argues that cost should not be the sole basis for deciding what to prescribe.

WHEN TO CALL

New-onset headache after age 50. This always warrants evaluation. Do not assume a new headache at midlife is migraine without having it checked.

Aura lasting longer than 60 minutes, aura consistently on one side, or aura that includes weakness or speech difficulty. These features require immediate neurological evaluation.

A sudden, severe headache unlike any you have had before. This requires emergency evaluation regardless of migraine history.

THIS WEEK

For the next four weeks, note each headache: the day, how long it lasted, severity, and whether any visual disturbance appeared. A note on your phone or a card in the medicine cabinet. This is the data a neurologist needs to identify the pattern and decide what to recommend.

If migraines have increased in frequency, changed in character, or now include aura for the first time, bring this to your doctor specifically. Ask whether a referral to a headache specialist is appropriate. The options available have changed significantly since 2018.

If you are taking estrogen-containing contraceptives and have developed migraine with aura, this is a safety conversation. The Centers for Disease Control and Prevention classifies combined hormonal contraceptives as unsafe for women with migraine with aura.

The four-week record is the single most useful thing you can bring to a headache consultation. A neurologist working from a verbal description of a few recent attacks has very little to act on. Four weeks of dated, graded attacks with aura noted gives a clinician enough information to recommend treatment. The data changes the conversation.

ONE TAP, NO FORM

How did the pattern change?

Tapping opens a pre-written reply. Nothing is public, nothing goes to a list. What most readers tap decides what gets explained next.

The migraines got more frequent

I started seeing flashing lights or blind spots before the pain

They used to follow my cycle and now they do not

I was told menopause would fix them and it did not

Or write in your own words. Every reply is read.

Read recent issues

EVERY SOURCE READ FOR THIS ISSUE

Five sources: one narrative review on migraine across the menopausal transition, one menopausal migraine review, one estrogen replacement and migraine review, one population study, and one professional body position statement.

1	Migraine across the menopausal transition and beyond: a narrative review Narrative review, Korn, Headache, 2026

2	Migraine and the menopause transition Review, PMC, 2026

3	Migraine, menopause and hormone replacement therapy Review, MacGregor, Post Reproductive Health, 2018

4	Migraine, menopause, and hormonal health Evidence summary citing 2025 population study of ~5,000 women, Cerebral Torque, 2026

5	CGRP-targeting therapies are a first-line option for the prevention of migraine Position statement, Charles et al., American Headache Society, Headache, 2024

Read more from The Cortisol Effect